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Background—Medication nonadherence rates are high. The factors predicting nonadherence in heart failure remain 
unclear.
Methods and Results—A sample of 202 adults with heart failure was enrolled from the northeastern United States and 
followed for 6 months. Specific aims were to describe the types of objectively measured medication adherence (eg, 
taking, timing, dosing, drug holidays) and to identify contributors to nonadherence 6 months after enrollment. Latent 
growth mixture modeling was used to identify distinct trajectories of adherence. Indicators of the 5 World Health 
Organization dimensions of adherence (socioeconomic, condition, therapy, patient, and healthcare system) were tested 
to identify contributors to nonadherence. Two distinct trajectories were identified and labeled persistent adherence 
(77.8%) and steep decline (22.3%). Three contributors to the steep decline in adherence were identified. Participants 
with lapses in attention (adjusted OR, 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and 
those with ≥2 medication dosings per day (OR, 2.59; P=0.016) were more likely to have a steep decline in adherence 
over time than to have persistent adherence.
Conclusions—Two distinct patterns of adherence were identified. Three potentially modifiable contributors to nonadherence 
have been identified. (Circ Heart Fail. 2012;5:430-436.)
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It is estimated that 20% to 50% of chronically ill patients in general,1 and 40% to 60% of adults with heart failure (HF) 
in particular,2 are nonadherent with medications. Number of 
hospitalizations, inpatient days, emergency department visits, 
healthcare costs, and mortality are higher in patients with HF 
who do not take their medications as prescribed.3–5
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Medication adherence is defined as the extent to which 
the patient’s medication-taking behavior corresponds with an 
agreed-on medication regimen from a healthcare provider.6 
Adherence requires both behavioral execution and persis-
tence in medication-taking.7 Four components are involved 
in the assessment of medication adherence: (1) taking adher-
ence (taking the prescribed medicines each day); (2) dosing 
adherence (taking the correct number of doses each day); (3) 
timing adherence (taking doses within ±2 hours of the time 
prescribed); and (4) avoiding drug holidays (eg, >48 hours 
between doses).
A wide variety of factors have been identified as 
contributors to medication nonadherence. The World 
Health Organization (WHO) groups factors influencing 
adherence into 5 dimensions.8 The socioeconomic dimension 
includes race and income. Condition-related factors include 
symptoms and depression. The therapy-related dimension 
includes treatment complexity. Patient-related factors are both 
physical (eg, cognitive impairment) and psychological/behav-
ioral (eg, health perceptions). Finally, healthcare system-
related factors include the high costs of drugs and receipt of 
specialty services.
Although numerous studies of medication nonadherence 
in adults with HF have been conducted, several gaps remain 
in our knowledge.1,2 Most studies of medication adherence in 
HF are cross-sectional in design and sample sizes are often 
small. Many different tools are used in measuring adherence, 
which makes it difficult to compare across studies. Self-report 
is the most commonly used method of adherence measure-
ment; we located only 4 studies using electronic monitoring 
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in patients with HF.5,9–11 Bivariate analyses testing single 
hypotheses have failed to provide an adequate picture of the 
manner in which factors interact to contribute to medication 
nonadherence in patients with HF.12,13
We previously demonstrated that adults with HF and exces-
sive daytime sleepiness (EDS) self-reported more problems 
adhering to their medication regimen than those without EDS. 
Lapses in attention interfered with the vigilance needed to 
remember their medications, leading to reports of nonadher-
ence.14 In this study we sought to build on these results and fill 
some of the knowledge gaps with objective data on medication 
nonadherence collected over a 6-month period using electronic 
monitoring technology manufactured by AARDEX (www.aar-
dex.com), the Medication Event Monitoring System (MEMS). 
The specific aims of this study were to identify and describe 
common and distinct trajectories of nonadherence (eg, taking, 
timing, dosing, drug holidays) during a prospective study of 
adults with HF and to identify contributors to medication non-
adherence using the 5 WHO model dimensions of adherence.
Methods
Design and Sample
The methods used in this study have been described previously 
and are summarized here.14 This was a prospective study of adults 
with Stage C chronic HF who were enrolled from 3 sites in the 
northeastern United States. One site was a university referral center, 
one was a Veterans Affairs Medical Center, and one was a regional 
medical center. Stage C, presence of previous or current symptoms 
of HF in persons with an underlying structural heart problem but 
managed with medical treatment, was confirmed based on echocar-
diographic and clinical evidence. Potential subjects were screened 
for visual and hearing adequacy and English literacy. Otherwise 
eligible individuals were excluded if they lived in a setting where 
medication administration was not an independent activity, if they 
worked nights or rotating shifts, or if they had renal failure requir-
ing dialysis, an imminently terminal illness, plans to move out of 
the area, or a history of serious drug or alcohol abuse within the 
past year. Those with a history of major depressive illness were 
excluded because depression is known to influence self-care.15 
Although both major and minor depression are associated with poor 
self-care,16 we excluded only those with major depression because 
some of the symptoms of depression mirror those of HF. Avoiding 
all symptoms of depression would have severely limited enrollment. 
Potential participants were screened with the 9-item Patient Health 
Questionnaire.17 Those reporting ≥5 of the 9 symptoms more than 
half the days in the past 2 weeks were excluded if one of the symp-
toms was depressed mood or anhedonia.
Institutional Review Board approval was obtained from all 3 
sites and all participants gave written informed consent. Data were 
collected at baseline and 3 and 6 months later by research assistants 
during home visits. These data were collected between 2007 and 
2010.
In total, 280 subjects were enrolled in the study. Attrition from the 
study was 13.6%; 242 finished the 6-month study and were included 
in the analytic data set. Reasons for attrition included death (n=6), 
too ill to continue (n=7), withdrawal (n=5), and loss to follow-up 
(n=20). For the current study, taking, dosing, timing, and drug holi-
day  components of medication nonadherence could only be described 
in the 202 subjects who used the MEMS device during the 6 months 
of the study. The 40 subjects who completed the study but did not 
use the MEMS device for the full 6 months were more likely to be 
nonwhite, to be taking a drug that needed to be taken more than once 
daily, to report worse health status, and to have objectively measured 
lapses in attention.
Measurement
Adherence to the medication regimen was assessed using MEMS. 
Unobtrusive microelectronic monitoring devices in the caps of medi-
cation containers document each time that the cap is removed from a 
medication vial. Real-time data are collected in the device and later 
downloaded to a personal computer and integrated with other data for 
analysis. Crossvalidation studies have shown that electronic moni-
toring using MEMS is more sensitive, reliable, and valid than other 
measurement techniques such as pill counts, biochemical assays, col-
lateral reports, or clinical judgment.18
MEMS data were collected on one medication scheduled to be 
taken at a fixed time. Others have shown that patient adherence with 
medications is generally consistent among drugs in the regimen when 
the side effects of specific medications are accounted for; thus, one 
medicine was used to minimize subject burden.19 Our first choice 
of drugs was an angiotensin-converting enzyme inhibitor because 
angiotensin-converting enzyme inhibitors may be taken more often 
in multiple daily doses than other drugs for HF and most patients 
are prescribed an angiotensin-converting enzyme inhibitor. If patients 
were not taking a multiple-dose angiotensin-converting enzyme in-
hibitor, an angiotensin II receptor blocker or a β-blocker was moni-
tored. The medicine allocated to the MEMS device was to be taken 
twice daily by 57.9% of participants and ≥3 times daily by 3% of par-
ticipants; others were taking their medicines once daily. Participants 
were fully informed about the functioning of the MEMS device and 
instructed on how to use and integrate the device into their daily rou-
tine. For patients who routinely used a pill box to organize their medi-
cines, we asked them to use the MEMS container in addition to the 
pill box. To facilitate this, a note was placed in the appropriate slot 
of the pill box to remind them to take the medicine out of the MEMS 
container. MEMS data were collected over the entire 6-month inter-
val and downloaded at 3 and 6 months. Deviations in use such as ac-
cidental openings were noted in study diaries and used to correct the 
MEMS data before analysis. There is evidence that use of the MEMS 
may influence medication-taking behavior initially. That is, patients 
may take their medications more consistently at first because they 
know they are being monitored.20 We took this into consideration by 
modeling trajectories of nonadherence as a function of MEMS data 
in 2 separate intervals.
The WHO dimensions were measured as follows (Table 1). Social 
and economic characteristics of race, household income, education, 
and practical support for self care were measured by self-report. 
Formal education is thought to be an inconsistent indicator of knowl-
edge in the United States so education was measured indirectly using 
oral reading scores on the revised American National Adult Reading 
Test.21 Scores range from 0 to 50 reflecting the number of irregular 
words (eg, bouquet, capon) pronounced correctly. Practical support 
for self-care was measured with a 7-item true/false survey measuring 
specific ways in which family and friends assist with the treatment 
regimen (eg, they remind me of things I need to do, they drive me 
places like the doctor’s office, they help me interpret my symptoms).
Condition-related influences included comorbid illnesses, depres-
sion, EDS, functional class, physical limitations, symptoms, social 
limitations, and quality of life. The number of comorbid illnesses 
was abstracted at enrollment from the medical record by regis-
tered nurses using the Charlson Index. The total score was used in 
analysis. Depression was assessed using the 2-item Patient Health 
Questionnaire.17 This short version of the 9-item Patient Health 
Questionnaire was used to avoid items assessing fatigue and sleepi-
ness, which were measured in other ways. Dichotomized scores 
on the Epworth Sleepiness Scale was used to measure EDS.22 To 
assess functional class, research assistants interviewed patients about 
activities causing symptoms using a structured interview.23 Interview 
results were used by a single board-certified cardiologist to score 
New York Heart Association functional class. Symptoms, physi-
cal limitations, social limitations, and quality of life were assessed 
using the Kansas City Cardiomyopathy Questionnaire, a 23-item 
disease-specific questionnaire.24 Responses are scored on a Likert 
scale, summed, and standardized to a scale of 100 with higher scores 
indicating better health status.
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The therapy-related dimensions specific to medication adherence 
included the total number of prescription medications taken daily and 
the prescribed dosing frequency for the medication used in the 
MEMS device. To capture the number of routine medications, 
 research assistants gathered information on every medicine taken 
during face-to-face visits, usually by direct review of medication 
containers.
Patient-related characteristics included sex, health perceptions, 
knowledge of HF, and cognition. Perceived overall health was mea-
sured with a single item: How would you rate your health? (fair, 
poor, good/very good). To assess HF knowledge, subjects complet-
ed the Dutch HF Knowledge Scale, a 15-item survey with a possible 
score range of 0 to 15. The scale measures HF knowledge in gen-
eral, knowledge of HF treatments, and HF symptom recognition.25 
Higher scores indicate more knowledge. We previously demonstrat-
ed that lapses in attention were the primary cognitive contributor to 
self-reported medication nonadherence.14 So, dichotomized scores 
on the Psychomotor Vigilance Task were used as the measure of 
cognition; >4.69 (transformed) lapses was judged as an abnormally 
high level of inattention.26
Healthcare system factors assessed were the participants’ percep-
tion that the cost of medications was a factor impairing medication 
adherence (yes or no) and the receipt of HF specialty care (yes or no). 
Both of these factors were assessed by self-report.
Statistical Analysis
Latent growth mixture modeling was used to identify distinct trajec-
tories of nonadherence. Growth mixture modeling identifies trajec-
tories that vary around different means and have unique estimates 
of variances, separate covariate influence, and homogenous within-
trajectory growth. Unlike deterministic methods of clustering that 
involve minimizing within-group and maximizing between-group 
variance, growth mixture modeling uses a model-based naturalistic 
approach wherein probabilities of trajectory membership are calcu-
lated. Cases are then assigned to a “most likely” trajectory and un-
certainty in trajectory membership is quantified. Our growth mixture 
modeling included taking (%), timing (%), and dosing adherence (%) 
and drug holidays (yes or no) recorded from the MEMS during the 
first 3 months and the second 3 months of the study. We compared fit 
among models with 2 to 5 trajectories using Mplus Version 6.0 (Los 
Angeles, CA). The Lo-Mendell-Rubin adjusted likelihood ratio test 
(P<0.05),27 parametric bootstrapped likelihood ratio test (P<0.05),28 
Bayesian Information Criterion,29 convergence (entropy near 1.0), 
the proportion of sample in each trajectory (not <5%), and poste-
rior probabilities (average posterior probability of belonging in “most 
likely” trajectory near 1.0) were used to compare alternative mod-
els (eg, k versus k-1 trajectories) and quantify model uncertainty.30,31 
Changes in adherence by trajectory were quantified using pairwise 
t tests, repeated-measures analysis of variance, or McNemar tests 
where appropriate. Out of concern for the potential effects of model 
saturation, predictors of unfavorable trajectories of medication ad-
herence were quantified using backward stepwise logistic regression 
modeling (P set to 0.20) in StataMP 11 (College Station, TX). ORs 
and 95% CIs were calculated for each model factor, and model fit was 
quantified using χ2, McFadden pseudo R2, and Hosmer-Lemeshow 
goodness-of-fit tests.
Results
The characteristics of these 202 subjects at study enrollment 
are shown in Table 2. The average subject was 63 years old, 
male (65.4%), white (68.3%), and had 2.8 comorbid condi-
tions. Most (54.9%) had government health insurance; only 
one individual was uninsured. Overall, there were significant 
yet heterogeneous increases in medication-taking nonadher-
ence (81.3%±25.8% versus 87.2%±19.4%; t=4.51; P<0.001), 
dosing nonadherence (73.2%±30.1% versus 79.7%±23.8%; 
t=4.89; P<0.001), and timing nonadherence (59.0%±32.8% 
versus 65.5%±29.6%; t=4.99; P<0.001) over time (ie, com-
paring data from the second 3 months with data from the first 3 
months of the study). Comparable proportions of patients took 
drug holidays during the second 3 months compared with the 
first 3 months of the study (47.0% versus 47.5%; P=0.177).
Using growth mixture modeling, we identified 2 distinct 
trajectories of nonadherence. Both the Lo-Mendell-Rubin test 
(781.8; P=0.0007) and parametric bootstrapped likelihood 
ratio test (811.23; P<0.001) supported 2 versus one trajectory, 
model entropy was 0.975, and sample size-adjusted Bayesian 
Information Criterion was 10719.3. Based on observed char-
acteristics, we labeled the first and largest trajectory (n=157 
[77.8%]) as a “persistent adherence” subgroup; average poste-
rior probability for membership in this trajectory was 98.3%. 
We labeled the second trajectory (n=45 [22.3%]) as a “steep 
decline” subgroup; average posterior probability for member-
ship in this trajectory was 99.6%.
As displayed in the Figure, those in the persistent adher-
ence subgroup had minimal changes in taking adherence 
during the study, whereas those in the steep decline subgroup 
had considerable declines in taking adherence during the 
study (F=80.33; P<0.001). Similar patterns existed among 
the 2 groups with respect to changes in dosing adher-
ence (F=72.9; P<0.001) and timing adherence (F=58.62; 
P<0.001). In addition, the frequency of drug holidays 
Table 1. Factors Tested as Potential Contributors to 
Medication Nonadherence
1. Social and economic dimension
 Race
 Household income
 Education
 Practical support for self-care
2. Condition-related dimension
 Comorbid illnesses
 Depression
 Excessive daytime sleepiness
 NYHA functional class
 KCCQ Physical limitations
 KCCQ symptom frequency, burden, stability
 KCCQ social limitations
 KCCQ quality of life
3. Therapy-related dimension
 No. of medications taken per day
 Dosing frequency of medicine used in the MEMS device
4. Patient-related dimension
 Sex
 Perceived overall health
 Knowledge of heart failure
 Cognition and attentiveness
5. Healthcare system dimension
 Cost of medications
 Receipt of heart failure specialty services
NYHA indicates New York Heart Association; KCCQ, Kansas City Cardiomy-
opathy Questionnaire; MEMS, medication electronic monitoring system.
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in creased slightly for patients in the persistent adher-
ence subgroup (38.9%–43.9%; P=0.172) and increased 
moderately in the steep decline subgroup (77.8%–84.4%; 
P<0.001).
Determinants of steep declines in adherence are presented 
in Table 3 (model χ2=24.7, P=0.0005, pseudo R2=13.5%; 
Hosmer-Lemeshow=65.32, P=0.636). Based on the WHO 
model, 3 contributors to a steep decline in adherence were 
identified. Specifically, participants with lapses in attention, 
those with EDS, and those with ≥2 medication dosings per 
day were more likely to have a steep decline in adherence over 
time than to have persistent adherence.
Discussion
To the best of our knowledge, this is the first study to explore 
patterns of objectively measured medication adherence using 
a naturalistic rather than a deterministic approach in adults 
with HF. In this study we identified 2 distinct trajectories: 
persistent adherence and a steep decline in medication adher-
ence. Taking, dosing, and timing adherence decreased sig-
nificantly over time in the steep decline subgroup and drug 
holidays were more common. Three likely contributors to a 
steep decline in adherence were identified: lapses in attention, 
EDS, and dosing frequency. These factors represent 3 of the 
5 WHO dimensions as predictors of nonadherence. No one 
dimension was overrepresented suggesting the usefulness of 
the WHO model in the analysis of this important issue.
The only therapy-related dimension we identified as impor-
tant in medication nonadherence was dosing frequency, 
which has been identified repeatedly as an important factor 
influencing medication adherence in chronically ill popula-
tions.1 Others have demonstrated that adherence is better with 
medications prescribed once versus twice daily.32,33 A similar 
relationship exists for once versus 3 times daily2,32,34 and once 
versus 4 daily doses.34 Some have suggested that taking a med-
ication 2 or 3 times daily is still better in promoting adherence 
than 4 times daily.35 Timing adherence also improves when 
the dosing regimen declines.1,19 These results should serve to 
remind clinicians of the importance of streamlining the dosing 
schedule whenever possible.
Excessive daytime sleepiness contributed to a steep decline 
in medication adherence over time, confirming our prior 
results obtained by self-report in this same sample.14 In that 
study, subjects with EDS and cognitive decline were 2.5 times 
as likely to report being nonadherent compared with subjects 
without EDS or cognitive decline. The component of cogni-
tion most associated with nonadherence was lapses in atten-
tion, which also confirms these results.
Finding that lapses in attention contribute to objectively 
measured nonadherence contributes to our growing under-
standing of medication nonadherence. Lim and Dinges36 state 
that sustaining attention is fundamental to successful cogni-
tive processing. If sustained attention is needed for memory, 
some patients with HF may not be able to sustain the atten-
tion needed to establish a consistent pattern of execution and 
persistence in medication-taking. Wu et al2 noted in their 
systematic review that forgetfulness was associated with 
nonadherence in all of the studies in which forgetfulness was 
examined. Together these results suggest that poor sleep may 
contribute to inattention, which together pose a significant risk 
for nonadherence. Factors other than sleep deprivation known 
to impair the ability to be attentive include anxiety, boredom, 
and distraction.37 In this sample, the most likely contributor to 
inattention was poor sleep. In a prior analysis we demonstrated 
that 21.8% of this sample had significant sleep dysfunction.38
Most authors have found medication nonadherence rates 
between 40% and 60% in patients with HF. In our study, taking 
Table 2. Characteristics of the Sample
(n=202)
Age, y 63.1±11.8
Male 132 (65.4)
Race/ethnicity
 White 138 (68.3)
 Nonwhite 64 (31.7)
Education
 Less than high school 17 (8.4)
 High school 68 (33.7)
 Some college 117 (57.9)
 ANART-R score 30.9±11.2
Household income
 More than enough 78 (38.6)
 Enough 92 (45.5)
 Not enough 32 (15.8)
Perceived overall health
 Good, very good 103 (51.0)
 Fair 78 (38.6)
 Poor 21 (10.0)
Total no. of comorbid conditions on Charlson Index 2.8±1.8
NYHA functional class
 Classes I and II 49 (24.3)
 Class III 119 (58.9)
 Class IV 34 (16.8)
Daily dosing with MEMS
 Once daily 79 (39.1)
 Twice daily 117 (57.9)
 Three times or more daily 6 (3.0)
No. of daily medications 9.9±3.8
High lapses on the PVT 71 (35.9)
Excessive daytime sleepiness (≥6) 112 (55.5)
Patient Health Questionnaire (PHQ2) 0.8±1.0
Self-care support score 1.5±1.5
Medication costs impair adherence 20 (10.3)
KCCQ Physical Limit Score 71.6±22.0
KCCQ Symptom Score 76.3±19.4
KCCQ Social Limitations Score 68.4±25.3
KCCQ Quality of Life Score 66.7±23.3
Dutch Knowledge Scale Score 11.7±1.7
Mean±SD or column no. (%) are reported.
ANART-R indicates revised American National Adult Reading Test; NYHA, 
New York Heart Association; MEMS, Medication Event Monitoring System; PVT, 
psychomotor vigilance task; KCCQ, Kansas City Cardiomyopathy Questionnaire; 
PHQ2, 2-item Patient Health Questionnaire.
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adherence averaged 81% to 87%, dosing adherence averaged 
73% to 80%, and timing adherence averaged 59% to 66% with 
considerable heterogeneity. Ours is a very different perspective 
on adherence, however, and it is important to recognize that we 
are not reporting an overall adherence rate. Instead, it is the pro-
portion of patients who were categorized as being persistently 
adherent. The persistent adherers had rates approximately 94% 
for taking adherence, approximately 89% for dosing adherence, 
and approximately 74% for timing adherence. As such, we can-
not compare this number with other average and direct calcu-
lations of overall adherence. What we can say is that 70.8% 
of patients fit the persistent adherence profile, which is not the 
same as saying the medication nonadherence rate was approxi-
mately 29%. We believe that this approach represents a signifi-
cant advance in how nonadherence is measured and examined.
Several of the factors anticipated to predict medication 
adherence were not significant predictors. Practical support for 
self-care was not significant in any of the models, although in 
the meta-analysis by DiMatteo,39 the odds of adherence were 
3.6 times higher among those who received practical support 
than among those who did not. Neither income nor the cost of 
medications was a significant predictor of adherence, contrary 
to what others have found.40,41 Minor depression also was not 
a significant predictor of adherence, although we cannot say 
anything about major depression because those individuals 
were excluded from enrollment. The most likely reason for 
the difference between our results and those of others is the 
method of measurement; most prior studies measured adher-
ence using self-report.
Further research is needed to determine if these results 
hold in larger samples of patients with HF. If corroborated, 
the 2 identified groups would likely benefit from very differ-
ent interventions. Those with persistent adherence probably 
need regular encouragement but no additional intervention 
resources. The patients with a steep decline in adherence 
over time may be particularly amenable to an intervention 
focused more on persistence than execution such as alarms 
and reminders when medications are due. Screening for 
patients with lapses in attention and daytime sleepiness can 
help identify those patients at risk for declining adherence. 
These patients also need a simplified medication dosing 
regimen. Providers are strongly encouraged to focus their 
efforts on simplifying the medication dosing regimen when-
ever possible.
Strengths and Limitations
A major strength of this study was the analysis approach, 
which allowed us to move beyond mean trends to examine 
heterogeneity and identify subgroups to explain the hetero-
geneity. The major limitation was that a small portion of the 
final sample failed to use the MEMS device for the full 6 
months, which limited the sample size available to analyze 
Figure. Two trajectories of adherence were identified for each of the 4 types of medication-taking behavior. In each type of adherence 
examined (taking, dosing, time adherence, and drug holidays), most participants were fairly adherent. In each of these types, however,  
a subgroup of participants was identified who demonstrated a steep decline in medication-taking behavior.
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Table 3. Logistic Regression Model Predicting Steep 
Declines in Adherence Using MEMS Data
Variable Grouped by Dimension
Steep Declines in Adherence 
OR (95% CI), P Value
Social and economic dimension
 White (versus nonwhite) 0.55 (0.23–1.28), 0.162
Condition-related dimension
 Depression 0.73 (0.48–1.12), 0.151
 Excessive daytime sleepiness 2.51 (1.06–5.95), 0.037
Therapy-related dimension
 2+ medication dosings per day 2.59 (1.19–5.64), 0.016
Patient-related dimension
 Lapses in attention on PVT 2.65 (1.14–6.16), 0.023
Healthcare system dimension
 Heart failure specialty services 1.77 (0.78–4.02), 0.173
Adjusted odds risk ratios are displayed with persistent adherence as the 
referent subgroup.
MEMS indicates Medication Event Monitoring System; PVT, psychomotor 
vigilance task.
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the specific types of medication nonadherence. Some of these 
participants may have been those using a pill box; perhaps 
using both a pill box and the MEMS device was too arduous 
for them. However, no data from these subjects were used in 
the analysis, so this was not judged to be a major limitation. 
Sensitivity analyses suggest that these findings might have 
been even more robust had all participants used the device 
because those without 6 months of MEMS data were sub-
jects with lapses in attention and multiple-dosing regimens. 
Moreover, our mean estimates and precision of ORs must be 
interpreted with an appreciation of the small subgroup and 
overall sample sizes. Although we were successful in identi-
fying unique subgroups of nonadherence and significant pre-
dictors thereof, additional testing in a larger sample would 
increase the precision of the OR estimates and further limit 
the risk of errors of the first and second kind.
In summary, in this study of adults with HF, we demon-
strated the complexity of medication adherence and the fac-
tors contributing to nonadherence. Clearly, nonadherence is a 
complex and multifaceted issue that defies a simple solution. 
These results, however, illustrate some potentially modifiable 
contributors to nonadherence that could be addressed in future 
intervention trials.
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CLINICAL PERSPECTIVE
As many as 60% of patients with heart failure are nonadherent in taking their medications. Hospitalizations, costs, and 
death are higher in patients with heart failure who do not take their medications as prescribed. In this study we followed 202 
adults with heart failure for 6 months, measuring their daily medication adherence electronically. Latent growth mixture 
modeling was used to identify patterns of adherence. The World Health Organization dimensions of adherence (socioeco-
nomic, condition, therapy, patient, and healthcare system) were tested to identify contributors to nonadherence. We identified 
2 distinct groups of patients: those (77.8%) who were persistently adherent in their medicines as prescribed and a subset 
(22.3%) who had a steep decline over time in adherence. Three contributors to the steep decline in adherence were identified: 
lapses in attention, excessive daytime sleepiness, and those taking a medication ≥2 times per day. Medications that need to 
be taken in multiple daily doses are known to be associated with poor adherence, but this study confirms the importance of 
prescribing once-a-day medicines whenever possible. Excessive daytime sleepiness and lapses in attention are likely cor-
related in that patients who do not sleep well are more sleepy during the day and may have trouble being sufficiently vigilant 
or attentive to remember to take their medicines. Thus, promoting sleep may be a modifiable factor that could improve 
medication adherence.
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